Understanding Endoscopic Disease Activity in IBD: How to Incorporate It into Practice

被引：28
作者：
Christensen B. [1 ,2 ]
Rubin D.T. [1 ]
机构：
[1] University of Chicago Medicine Inflammatory Bowel Disease Center, 5841 S. Maryland Ave., MC4076, Room M410, Chicago, 60637, IL
[2] Department of Gastroenterology, Alfred Hospital and Monash University, Melbourne
来源：
Current Gastroenterology Reports | 2016年 / 18卷 / 1期
关键词：
Colonoscopy; Crohn’s disease; Disease activity indices; Endoscopic disease activity; Inflammatory bowel disease; Mucosal activity; Mucosal healing; Ulcerative colitis;
D O I：
10.1007/s11894-015-0477-6
中图分类号：
学科分类号：
摘要：
Endoscopic assessment of disease activity is an essential part of clinical practice in inflammatory bowel disease (IBD) and is used for diagnosis, prognosis, monitoring for dysplasia and increasingly for the evaluation of mucosal or endoscopic response to therapy. Recently, mucosal or endoscopic healing has emerged as a key goal of therapy as it has been found that patients who achieve endoscopic remission have improved outcomes compared to those who do not, and this may be independent of their clinical disease activity. However, there is currently no validated definition of mucosal healing and there are numerous endoscopic scoring systems proposed to define endoscopic activity and response to therapy in both ulcerative colitis and Crohn’s disease. This article will discuss the most common endoscopic scores used to measure endoscopic disease activity in IBD, the pros and cons of each of these scoring systems and proposed definitions for endoscopic response or remission that exist for each. In addition, the role of endoscopy in prognosticating the disease course is discussed and how endoscopy can be utilized as part of a “treat-to-target” treatment strategy where endoscopy results direct decisions regarding medical strategies in clinical practice is highlighted. © 2016, Springer Science+Business Media New York.
引用
收藏
页码：1 / 11
页数：10
相关论文
共 77 条
  • [71] Peyrin-Biroulet L., Et al., Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn’s disease in the SONIC trial, Gut, 63, 1, pp. 88-95, (2014)
  • [72] Halpin S.J., Ford A.C., Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis, Am J Gastroenterol, 107, 10, pp. 1474-1482, (2012)
  • [73] Bouguen G., Treat to target: a proposed new paradigm for the management of Crohn’s disease, Clin Gastroenterol Hepatol, 13, 6, pp. 1042-1050, (2015)
  • [74] Bouguen G., Et al., Feasibility of endoscopic assessment and treating to target to achieve mucosal healing in ulcerative colitis, Inflamm Bowel Dis, 20, 2, pp. 231-239, (2014)
  • [75] Bouguen G., Et al., Endoscopic assessment and treating to target increase the likelihood of mucosal healing in patients with Crohn’s disease, Clin Gastroenterol Hepatol, 12, 6, pp. 978-985, (2014)
  • [76] De Cruz P., Et al., Mucosal healing in Crohn’s disease: a systematic review, Inflamm Bowel Dis, 19, 2, pp. 429-444, (2013)
  • [77] Peyrin-Biroulet L., Et al., Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target, Am J Gastroenterol, 110, pp. 1324-1328, (2015)
12345678